Multiomic Diagnostics in Youth With Psychosis

Status Recruiting

Clinical Trial Summary

Rady Children's Institute for Genomic Medicine seeks to understand the genomes and immune systems in 15 children and adolescents who are admitted to Rady Children's Hospital Child and Adolescent Psychiatry Service with psychotic symptoms or schizophrenia. Cutting-edge genome and protein sequencing technology will be used to better understand how immunological and genetic assessments may improve our ability to identify the cause of psychosis and impact care. The investigator also hopes to identify new genetic and/or autoimmune causes of psychosis that may inform new treatment for future patients.

Clinical Trial Description

Schizophrenia is a severe mental illness that often starts in late adolescence or early adulthood where individuals experience changes in how they perceive and interact with the world around them (psychosis). These extreme changes in how one perceives and interacts with the world can cause great distress and have a very negative impact on one's life. In most cases, the cause of schizophrenia or psychosis is unknown. However, in a small subset of people who develop schizophrenia or psychosis, their own immune system creates antibodies that attack the brain, which leads to psychosis (autoimmune psychosis). In another subset of patients, there are specific genetic changes that serve as major risk factors for developing psychosis. Identifying autoimmune and genetic factors associated with psychosis with psychosis can inform diagnosis, treatment and prognosis. However, it is still currently unknown how frequently these autoimmune and genetic factors are present in adolescents presenting to the hospital with their first psychotic episode and whether testing for them impacts care. The investigator proposes a deep analysis of both genomes and immune systems of 15 children and adolescents who are admitted to Rady Children's Hospital Child and Adolescent Psychiatry Service with new psychotic symptoms or schizophrenia. The investigator plans to use cutting-edge genome and protein sequencing technology to better understand how immunological and genetic assessments may improve our ability to identify the cause of psychosis and impact care. The investigator also hopes to identify new genetic and/or autoimmune causes of psychosis that may inform new treatments for future patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05457140
Study type	Interventional
Source	Rady Pediatric Genomics & Systems Medicine Institute
Contact	Aaron Besterman, MD
Phone	858-576-1700
Email	abesterman@health.ucsd.edu
Status	Recruiting
Phase	N/A
Start date	October 10, 2022
Completion date	August 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04929938` - Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients	N/A
Recruiting	`NCT05863572` - Strengthening Care in Collaboration With People With Lived Experience of Psychosis in Uganda	N/A
Completed	`NCT04277585` - Improving Access to Early Psychosis Coordinated Specialty Care	N/A
Recruiting	`NCT06197048` - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder	N/A
Completed	`NCT04284813` - Families With Substance Use and Psychosis: A Pilot Study	N/A
Terminated	`NCT04404712` - FAAH Availability in Psychiatric Disorders: A PET Study	Early Phase 1
Recruiting	`NCT05769933` - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Recruiting	`NCT04298450` - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention	N/A
Not yet recruiting	`NCT05558332` - Youth Nominated Support Team	N/A
Not yet recruiting	`NCT05358457` - Pilot Study to Evaluate the Effectiveness of Online Familiar Metacognitive Training (MCTf)	N/A
Not yet recruiting	`NCT03807388` - ReMindCare App for Patients From First Episode of Psychosis Unit.	N/A
Completed	`NCT02895269` - COllaborative Shared Care to IMprove Psychosis Outcome	N/A
Recruiting	`NCT02622048` - Understanding and Helping Families: Parents With Psychosis	N/A
Completed	`NCT02653729` - Cbt for Psychosis and Affect on Psychosis Symptoms	Phase 2
Completed	`NCT02733575` - Compassion Focused Therapy for Distressing Experiences	N/A
Completed	`NCT02531243` - Computer-Aided Learning for Managing Stress	N/A
Not yet recruiting	`NCT02244970` - Mindfulness RCT for Early Psychosis	N/A
Enrolling by invitation	`NCT01364818` - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment	N/A
Withdrawn	`NCT00786318` - Ziprasidone vs Standard Therapy for Agitated Patients in the ED	Phase 4
Recruiting	`NCT00722163` - A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis	Phase 0

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.